Previous 10 | Next 10 |
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...
BELLUS Health press release (NASDAQ:BLU): Q1 GAAP EPS of -$0.13 beats by $0.06. Revenue of $4K (flat Y/Y). For further details see: BELLUS Health GAAP EPS of -$0.13 beats by $0.06, revenue of $4M
- End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) scheduled for June of 2022; Plan to initiate the Phase 3 program in the second half of 2022 - - Three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTHE trial will b...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...
Gainers: Universal Display Corporation (OLED) +10%. United Airlines Holdings (UAL) +8%. Seres Therapeutics (MCRB) +7%. Tesla (TSLA) +7%. Sono Group (SEV) +7%. Losers: Xilio Therapeutics (XLO) -14%. BELLUS Health (BLU) -7%. Sleep Number Corporation (SNBR)...
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...
BELLUS Health press release (NASDAQ:BLU): FY GAAP EPS of -$0.90 beats by $0.01. Revenue of $16K. For further details see: BELLUS Health GAAP EPS of -$0.90 beats by $0.01, revenue of $16K
- Announced positive topline results from the Phase 2b SOOTHE clinical trial in refractory chronic cough (“RCC”), positioning BLU-5937 as a potentially best-in-class P2X3 antagonist - - Plans to request an End-of-Phase 2 meeting with the Food and Drug Administrat...
News, Short Squeeze, Breakout and More Instantly...
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health Canada NewsWire LONDON , June 28, 2023 /CNW/ - GSK plc (LSE: GSK) (NYSE: GSK) and BELLUS Health Inc. (TSX: BLU) NASDAQ: BLU) today announced GSK has completed ...
BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced the positive outcome of the BELLUS shareholders (“ Shareholders ”) vote at this morning’s special meeting of the Shareholders (the “ ...
Special Meeting to be held on June 16, 2023 BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU.TO) (“ BELLUS ” or the “ Company ”) today announced that the Superior Court of Québec has issued an interim order authorizing, among other things, the holding o...